Q3 EPS Estimates for Revolution Medicines Boosted by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD) – Analysts at Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a report issued on Tuesday, June 24th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of $0.12 per share for the quarter, up from their previous forecast of ($1.21). Wedbush has a “Outperform” rating and a $73.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($3.41) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at $1.97 EPS.

Several other brokerages also recently issued reports on RVMD. Needham & Company LLC reissued a “buy” rating and set a $57.00 target price on shares of Revolution Medicines in a research note on Tuesday. Stifel Nicolaus dropped their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Oppenheimer upped their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $80.00 price target on shares of Revolution Medicines in a research note on Wednesday. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, Revolution Medicines has an average rating of “Buy” and an average target price of $67.58.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $36.91 on Friday. The stock has a fifty day moving average of $39.61 and a 200-day moving average of $39.99. Revolution Medicines has a one year low of $29.17 and a one year high of $62.40. The company has a market capitalization of $6.88 billion, a PE ratio of -9.23 and a beta of 1.10.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period last year, the business posted ($0.70) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of RVMD. Boxer Capital Management LLC bought a new position in Revolution Medicines in the 4th quarter worth approximately $187,184,000. Janus Henderson Group PLC raised its position in Revolution Medicines by 54.5% in the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company’s stock worth $414,777,000 after purchasing an additional 3,346,755 shares during the last quarter. Lunate Capital Ltd bought a new position in Revolution Medicines in the 1st quarter worth approximately $77,658,000. Vanguard Group Inc. raised its position in Revolution Medicines by 14.7% in the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company’s stock worth $747,799,000 after purchasing an additional 2,185,082 shares during the last quarter. Finally, Farallon Capital Management LLC raised its position in Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company’s stock worth $579,498,000 after purchasing an additional 1,931,000 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.